BCL2 and ovarian cancer: HATMSC-MVs with high probability activate the apoptosis process in the target ovarian cancer cells because they are able to release a number of pro-apoptotic factors (e.g., bad, BIM, caspase 3, p27, p53, and others), and this process does not allow for spontaneous repair of damaged cancer cells despite the simultaneous release of anti-apoptotic proteins (e.g., bcl-2, HSP-60, p21, and others) by HATMSC2-MVs.